1.40E+07

Cell Line Description

1.4E7 is a hybrid cell line formed by the electrofusion of a primary culture of human pancreatic islets with PANC-1, a human pancreatic ductal carcinoma cell line (ECACC catalogue number 87092802). 1.4E7 has been shown to be tumourigenic when transplanted into a SCID mouse host. The cell line has applications in the study of pancreatic cell biology. 1.4E7 cells provide a method of producing pure insulin secreting cells when stimulated. This is an alternative to the use of primary tissue in cell transplantation therapies for type 1 diabetes. The Y chromosome could not be detected in this cell line by short tandem repeat (STR)-PCR analysis when tested at ECACC. It is a known phenomenon that due to the increased genetic instability of cancer cell lines the Y chromosome can be rearranged or lost resulting in lack of detection. The cell line is identical to the source provided by the depositor based on the STR-PCR analysis.

DNA Profile

STR-PCR Data:
Amelogenin: X
CSF1PO: 10,12
D13S317: 11
D16S539: 11
D5S818: 11,13
D7S820: 8
THO1: 7,8
TPOX: 8,11
vWA: 15

Culture Medium

RPMI-1640 + 2 mM Glutamine + 10% FCS / FBS

Subculture Routine

Split sub-confluent cultures (70-80%) 1:2 to 1:6 , i.e., seeding at 2-4 x 10⁴ cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37 °C. Population doubling approx 26hrs. At confluence 10⁵ cells/cm² can be expected.

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Legal Information

Flatt P & McClenaghan N (2004) Insulin producing cell-line US patent number 20040005702 (A1). Also WO0210346 (A2).

Disclaimer

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.